Finnish
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Sivu 1 alkaen 81 tuloksia
Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases
Vain rekisteröityneet käyttäjät voivat kääntää artikkeleita
Kirjaudu sisään Rekisteröidy
This invention relates to inhibitors of cysteine proteases, in particular to heteroaryl nitrile cathepsin K inhibitors and to their pharmaceutical use for the treatment or prophylaxis of diseases or medical conditions in which cathepsin K is implicated.
Cathepsin K is a member of the family of
S-(carboxymethyl)-cysteine pharmaceutical compound and preparation method and use thereof
Vain rekisteröityneet käyttäjät voivat kääntää artikkeleita
Kirjaudu sisään Rekisteröidy
CROSS REFERENCE TO RELATED APPLICATIONS
The present application is a national phase entry under 35 U.S.C. .sctn. 371 of International Application No. PCT/CN2013/078856, filed Jul. 5, 2013, of which is hereby incorporated herein by reference.
TECHNICAL FIELD
The present invention belongs to the field
3,4-Disubstituted azetidin-2-one derivatives useful as cysteine proteinase regulators
Vain rekisteröityneet käyttäjät voivat kääntää artikkeleita
Kirjaudu sisään Rekisteröidy
BACKGROUND OF THE INVENTION
Cysteine proteinases containing a highly reactive cysteine residue with a free thiol group at the active site have been known as playing an important role in certain conditions distinguished by aberrant protein turnover such as: muscular dystrophy (Am. J. Pathol. 1986,
4-substituted-3-(2-amino-2-cycloalkyl methyl)-acetamido azetidin-2-one derivatives as cysteine proteinase regulators
Vain rekisteröityneet käyttäjät voivat kääntää artikkeleita
Kirjaudu sisään Rekisteröidy
BACKGROUND OF THE INVENTION
Cysteine proteinases containing a highly reactive cysteine residue with a free thiol group at the active site have been known as playing an important role in certain conditions distinguished by aberrant protein turnover such as: muscular dystrophy (Am. J. Pathol. 1986,
4-substituted-3-(2-amino-2-cycloalkyl methyl)-acetamido azetidin-2-one derivatives as cysteine proteinase regulators
Vain rekisteröityneet käyttäjät voivat kääntää artikkeleita
Kirjaudu sisään Rekisteröidy
BACKGROUND OF THE INVENTION
Cysteine proteinases containing a highly reactive cysteine residue with a free thiol group at the active site have been known as playing an important role in certain conditions distinguished by aberrant protein turnover such as: muscular dystrophy (Am. J. Pathol. 1986,
Substituted amino bicyclic-.beta.-lactam penam and cepham derivatives as cysteine protease inhibitors
Vain rekisteröityneet käyttäjät voivat kääntää artikkeleita
Kirjaudu sisään Rekisteröidy
BACKGROUND OF INVENTION
Cysteine proteases, such as cathepsins B, H, K, L, S, and O.sub.2, containing a highly reactive cysteine residue with a free thiol group at the active site have been known as playing an important role in certain conditions distinguished by aberrant protein turnover such as:
Thiadiazole compounds useful as inhibitors of cysteine activity dependent enzymes
Vain rekisteröityneet käyttäjät voivat kääntää artikkeleita
Kirjaudu sisään Rekisteröidy
FIELD OF THE INVENTION
This invention relates to novel compounds and their pharmaceutically acceptable acid addition salts and base addition salts for use in the treatment of acne, common cold, inflammatory joint disease by inhibition of cysteine proteases and cysteine activity dependent enzymes. In
Thiadiazole compounds useful as inhibitors of cysteine activity dependent enzymes
Vain rekisteröityneet käyttäjät voivat kääntää artikkeleita
Kirjaudu sisään Rekisteröidy
FIELD OF THE INVENTION
This invention relates to novel compounds and their pharmaceutically acceptable acid addition salts and base addition salts for use in the treatment of acne, common cold, inflammatory joint disease by inhibition of cysteine proteases and cysteine activity dependent enzymes. In
Anti-inflammatory peptides, and uses thereof
Vain rekisteröityneet käyttäjät voivat kääntää artikkeleita
Kirjaudu sisään Rekisteröidy
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a 371 National Phase Entry of International Patent Application No. PCT/EP2016/067090 filed on Jul. 18, 2016 which claims benefit under 35 U.S.C. .sctn. 119(b) of EP Application No. 15177013.8 filed Jul. 16, 2015 and EP Application No.
Cysteine, N-acetylcysteine, and penicillamine related compounds, pharmaceutical compositions thereof, and methods of use
Vain rekisteröityneet käyttäjät voivat kääntää artikkeleita
Kirjaudu sisään Rekisteröidy
FIELD
Disclosed herein are cysteine, N-acetylcysteine, and penicillamine prodrugs, pharmaceutical compositions comprising cysteine, N-acetylcysteine, and penicillamine prodrugs, and methods of using cysteine, N-acetylcysteine, and penicillamine prodrugs and pharmaceutical compositions thereof for
Cysteine-containing peptides having antioxidant properties
Vain rekisteröityneet käyttäjät voivat kääntää artikkeleita
Kirjaudu sisään Rekisteröidy
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention generally relates to human lipid metabolism, particularly to HDL-related proteins, their mutations, and peptides designed based on these mutations which have antioxidant properties beneficial in the regulation of cardiovascular
Cysteine-containing peptides having antioxidant properties
Vain rekisteröityneet käyttäjät voivat kääntää artikkeleita
Kirjaudu sisään Rekisteröidy
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention generally relates to human lipid metabolism, particularly to HDL-related proteins, their mutations, and peptides designed based on these mutations which have antioxidant properties beneficial in the regulation of cardiovascular
Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same
Vain rekisteröityneet käyttäjät voivat kääntää artikkeleita
Kirjaudu sisään Rekisteröidy
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention generally relates to the field of HDL-associated proteins and paraoxonase activity. More specifically, the invention provides a method of modulating paraoxonase activity using apolipoprotein A-I mutant peptides having cysteine
Thiazolidine prodrugs for the improved delivery of anti-inflammatory corticosteroids
Vain rekisteröityneet käyttäjät voivat kääntää artikkeleita
Kirjaudu sisään Rekisteröidy
TECHNICAL FIELD OF THE INVENTION
The present invention relates to certain selected novel 3,2'-spiro(1',3'-thiazolidine)steroids which are transient prodrug forms of conventional anti-inflammatory steroids (e.g., cortisone, hydrocortisone, prednisone, prednisolone, and the like) useful in alleviating
Protein product for treatment of infectious diseases and related inflammatory processes
Vain rekisteröityneet käyttäjät voivat kääntää artikkeleita
Kirjaudu sisään Rekisteröidy
CROSS-REFERENCE TO RELATED APPLICATIONS
The present Application is a US national phase of PCT/ES2008/000177 filed on Mar. 27, 2008 ("PCT Application"), which claims priority from Spanish Application No. P200700893 filed on Mar. 28, 2007, both of which are hereby incorporated by reference in their
Täydellisin lääketieteellinen tietokanta tieteen tukemana
- Toimii 55 kielellä
- Yrttilääkkeet tieteen tukemana
- Yrttien tunnistaminen kuvan perusteella
- Interaktiivinen GPS-kartta - merkitse yrtit sijaintiin (tulossa pian)
- Lue hakuusi liittyviä tieteellisiä julkaisuja
- Hae lääkekasveja niiden vaikutusten perusteella
- Järjestä kiinnostuksesi ja pysy ajan tasalla uutisista, kliinisistä tutkimuksista ja patenteista
Kirjoita oire tai sairaus ja lue yrtteistä, jotka saattavat auttaa, kirjoita yrtti ja näe taudit ja oireet, joita vastaan sitä käytetään.
* Kaikki tiedot perustuvat julkaistuun tieteelliseen tutkimukseen
